The Endocrine Society

Empagliflozin Use Could Reduce Risk of Kidney Stones in T2D

June 16, 2022

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

Fezolinetant Reduces Menopause Symptoms, Could Improve Sleep

June 15, 2022

New data from the SKYLIGHT 2 trial demonstrate the reductions in frequency and severity of vasomotor menopausal symptoms in midlife women associated with the use of fezolinetant as well as potential improvements in sleep associated with use of the neurokinin-3 receptor antagonist from Astellas Pharma.

In Pediatric T1D, Race, Income, & Insurance Type Remain Significant Barriers to Insulin Pump Use

June 14, 2022

An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.